

Proteomics International Laboratories Limited (PILL) [ASX: PIQ] applies its disruptive technology platform to study the structure and function of proteins, focusing on the discovery of new diagnostic biomarkers.

PILL has developed a unique predictive test for diabetic kidney disease – known as PromarkerD, and has recently signed a million-dollar licensing deal for its commercialisation in the US Territory of Puerto Rico. PILL is currently expanding its diagnostics portfolio using the Promarker discovery platform, and is investigating protein ‘fingerprints’ to diagnose other conditions with unmet need (including endometriosis and mesothelioma).

PILL operates in three integrated areas unified by its proprietary proteomics-based technology platform: *Diagnostics*, *Peptide drug discovery* and *Analytical services* (specialising in biosimilars). This sustainable business model merges blue sky opportunities with cash flow, using revenue generated from analytical services to fund pioneering research into next generation diagnostic tests and drug discovery.